跳至主要内容
临床试验/NCT04121845
NCT04121845已完成不适用

The Influence of Coronary Sinus Reducer Implantation on Exertional Capacity, Extent of Myocardial Ischemia and hrECG Markers of Arrhythmogenicity in Patients With Refractory Angina Pectoris

University Medical Centre Ljubljana2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2019年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
2
主要终点
Impact of CSR versus placebo procedure on exertional capacity measured by maximal oxygen consumption (VO2) during cardio-pulmonary exercise testing.

研究概览

简要总结

Patients with refractory angina pectoris have low quality of life and reduced exertional capacity. Studies have shown that the coronary sinus reducer (CSR) implantation improves the quality of life. However, to date there are no firm objective data on improvement of exertional capacity. Studies have shown a large influence of placebo effect after interventional procedures, which is even more pronounced than in medically treated patients. As angina pectoris presents entirely subjective perception of chest discomfort, its improvement may be influenced by this effect in up to 30 %. The investigators will study weather the CSR implantation improves aerobic exertional capacity in comparison to optimal medical therapy alone. Further, the investigators will explore the extent of myocardial reversible ischemia reduction and possible influence on hrECG markers of left ventricular arrhythmogenicity. 40 patients with refractory angina CCS class (Canadian cardiovascular society) II-IV and confirmed reversible ischemia will be included. Patients will be randomized into two groups. The first group will undergo CSR implantation procedure. The second group will present a sham control group with placebo procedure. At inclusion and after 6 months the investigators will perform cardiopulmonary exercise test (CPET), single photon emission tomography for detection of reversible ischemia (SPECT), high resolution ECG (hrECG), echocardiography and asses the subjective burden of angina according to CCS score and the quality of life according to the Seattle angina Questionnaire (SAQ).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

盲法说明

Punction of the right internal jugular vein and CSR implantation procedure simulation.

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • angina pectoris CCS class II-IV
  • receiving optimal medical therapy for at least one month
  • confirmed reversible myocardial ischemia in left anterior descending coronary artery (LAD) and/or left circumflex coronary artery (LCX) territory by SPECT
  • not candidate for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)

排除标准

  • recent non stable angina pectoris (within 1 months)
  • recent acute coronary syndrome (within 3 months)
  • recent successful PCI and/or CABG (within 6 months)
  • decompensated heart failure and/or recent (within 3 months) hospitalization due to heart failure
  • severe heart valve(s) disease
  • advanced chronic obstructive pulmonary disease (COPD) or poorly managed asthma
  • peripheral arterial disease, musculoskeletal disorder or central nervous system disease which preclude exercise testing

结局指标

主要结局

Impact of CSR versus placebo procedure on exertional capacity measured by maximal oxygen consumption (VO2) during cardio-pulmonary exercise testing.

时间窗: 6 months

Maximal oxygen consumption on cycle spiroergometry using the same ramp exercise protocol during the same part of the day.

次要结局

  • Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography (static scintigraphy).(6 months)
  • Change in QT variability as assessed by hrECG.(6 months)
  • Change in Canadian Cardiovascular Society angina pectoris class (CCS).(3 months, 6 months)
  • Impact of CSR versus placebo procedure on exercise duration time during cardio-pulmonary exercise testing.(6 months)
  • Change in the extent of myocardial reversible ischemia calculated by single-photon emission computed tomography (dynamic scintigraphy).(6 months)
  • Change in RR interval variability as assessed by hrECG.(6 months)
  • Impact of CSR versus placebo procedure on quality of life according to Seattle angina questionnaire (SAQ).(3 months, 6 months)
  • Change in late potentials as assessed by hrECG.(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Matjaž Bunc

Head of catheterization laboratory

University Medical Centre Ljubljana

研究点 (2)

Loading locations...

相似试验

CoROnary SinuS Reducer implantatiOn for ischemiA... | 临床试验